CaltechAUTHORS
Published March 1, 2024 | Version Correction
Erratum Open

Author Correction: Advances and prospects for the Human BioMolecular Atlas Program (HuBMAP)

Creators

  • 1. ROR icon California Institute of Technology

Abstract

The Human BioMolecular Atlas Program (HuBMAP) aims to create a multi-scale spatial atlas of the healthy human body at single-cell resolution by applying advanced technologies and disseminating resources to the community. As the HuBMAP moves past its first phase, creating ontologies, protocols and pipelines, this Perspective introduces the production phase: the generation of reference spatial maps of functional tissue units across many organs from diverse populations and the creation of mapping tools and infrastructure to advance biomedical research.

Copyright and License

© Springer Nature Limited 2023. 

Errata

Correction to: Nature Cell Biology https://doi.org/10.1038/s41556-023-01194-w. Published online 19 July 2023.

In the version of this article originally published, the name of Tianyang Xu was misspelled as Tiangyang Xu. The name has been corrected in the HTML and PDF versions of the article.

Code Availability

The HuBMAP Consortium GitHub at https://github.com/hubmapconsortium has 120 repositories that support data ingest, analysis, visualization and search plus HRA construction and usage. Documentation is available at https://software.docs.hubmapconsortium.org/apis.html.

Acknowledgement

We thank L. M. McGuire, SciStories, F. Goncalves, H. Schlehlein and V. A. Deshpande for their efforts in designing and creating graphics. We thank A. Honkala for assistance with manuscript formatting. We thank Z. Galis from the National Heart, Lung, and Blood Institute for many useful comments. Support for title page creation and format was provided by AuthorArranger, a tool developed at the National Cancer Institute. The authors gratefully acknowledge NIH HuBMAP grants U54HL165442 and U01HL166058 (L.P.); U54DK134301 and OT2OD033753 (S.J.); U54EY032442, U54DK120058 and U54DK134302 (J.M.S.); OT2OD033756 and OT2OD026671 (K.B.); UH3CA246635 (N.L.K.); UG3CA256967 (H.L.); U54HG010426 (M.P.S.); UH3CA246633 (M.A.); U54HD104393 (L.C.L. and P.R.); U54DK127823 (E.S.N., J.P.C. and W.-J.Q.); OT2OD033758 (N.G.); UH3CA246594 (F.G.); U54EY032442 and U54DK134302 (J.P.G.); U54HL145611 (S.L. and Y.L.); U01HG012680 (A.N.); U54DK120058, U54EY032442 and U54DK134302 (B.R.S.); UG3CA256959 (M.Z.); and U54HL165440 (I.S.V.). The authors are also supported by these grants: 2U01DK114933, P50DK133943 and U24DK135157 (S.J.); U54HL145608 and U54HL165443 (J.S.H.); U24CA268108 and U2CDK114886 (K.B.); Department of Defense W81XWH-22-1-0058 and Additional Ventures (L.P.). J.W.H. was supported by an NIH T32 Fellowship (T32CA196585) and an American Cancer Society: Roaring Fork Valley Postdoctoral Fellowship (PF-20-032-01-CSM). This work was supported, in part, by the Intramural Research Program of the NIH, National Institute of Allergy and Infectious Diseases (NIAID) and National Cancer Institute (NCI) (A.J.R.). These authors contributed equally: Sanjay Jain, Liming Pei, Jeffrey M. Spraggins, Katy Börner, Michael P. Snyder. Contributions. S.J., L.P., J.M.S., K.B. and M.P.S. conceived the idea and wrote the first draft of the manuscript and revisions. M.A., J.P.C., N.G., F.G., J.P.G., J.S.H., J.W.H., N.L.K., L.C.L., S.L., Y.L., H.L., A.N., E.S.N., W.-J.Q., A.R., P.R., B.R.S., R.V., I.S.V. and M.Z. contributed to manuscript revision. 

Conflict of Interest

Competing interests. The authors declare the following competing interests. F.G. is an employee of GE Research. B.R.S. is an inventor on patents and patent applications involving small-molecule-drug discovery and the 3F3 anti-Ferroptotic Membrane (3F3-FMA) antibody; co-founded and serves as a consultant to Inzen Therapeutics, Nevrox, Exarta Therapeutics and ProJenX; and serves as a consultant to Weatherwax Biotechnologies and Akin Gump Strauss Hauer and Feld. M.P.S. is a co-founder and an advisory board member of Personalis, Qbio, January AI, Mirvie, Filtricine, Fodsel, Lollo and Protos. I.S.V. consults for Guidepoint Global, Cowen, Mosaic and NextRNA. N.G. is a co-founder and an equity owner of Datavisyn. H.L. is a co-founder and an equity owner of ExoMira Medicine. The remaining authors declare no competing interests.

Files

s41556-024-01384-0.pdf

Files (505.0 kB)

Name Size Download all
md5:86cf0b8d4ff5392a0b74a4709349c288
505.0 kB Preview Download

Additional details

Related works

Is correction of
Journal Article: https://authors.library.caltech.edu/records/44139-r9855 (URL)

Funding

NIH
U54HG010426
NIH
OT2OD033753
NIH
U01DK114933
NIH
P50DK133943

Caltech Custom Metadata

Caltech groups
Division of Biology and Biological Engineering (BBE)
Publication Status
Erratum